Xeris insider plans sale of 20,000 common shares

Xeris Biopharma Holdings, Inc. insider Steven Pieper filed to sell common stock under Rule 144.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. insider Steven Pieper filed to sell common stock under Rule 144. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed to handle the planned sale of 20,000 common shares on NASDAQ with an aggregate market value of $167,800.00. The shares relate to Restricted Stock Units granted on 01/03/2025. During the prior three months, Pieper reported 10b5-1 plan sales of 27,600 shares for $235,276.20 on 07/07/2026 and 17,400 shares for $147,900.00 on 07/06/2026.

Key Figures

Planned shares to be sold: 20,000 shares Aggregate market value of planned sale: $167,800.00 10b5-1 sale on 07/07/2026: 27,600 shares for $235,276.20 +2 more

5 metrics

Planned shares to be sold 20,000 shares Common stock planned for sale through Morgan Stanley Smith Barney LLC

Aggregate market value of planned sale $167,800.00 Value associated with 20,000 Xeris Biopharma common shares

10b5-1 sale on 07/07/2026 27,600 shares for $235,276.20 Common stock sold under a 10b5-1 plan

10b5-1 sale on 07/06/2026 17,400 shares for $147,900.00 Common stock sold under a 10b5-1 plan

Grant date of RSUs 01/03/2025 Restricted Stock Units related to the shares to be sold

Key Terms

Rule 144, Restricted Stock Units, 10b5-1

3 terms

Rule 144 regulatory

"insider Steven Pieper filed to sell common stock under Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"The shares relate to Restricted Stock Units granted on 01/03/2025."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 regulatory

"During the prior three months, Pieper reported 10b5-1 plan sales of 27,600 shares."

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is Steven Pieper planning for XERS under Rule 144?

Steven Pieper plans to sell 20,000 shares of Xeris Biopharma common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $167,800.00, as disclosed in a Rule 144-related notice.

What type of XERS securities is Steven Pieper planning to sell?

The planned sale involves common stock of Xeris Biopharma Holdings, Inc., originating from Restricted Stock Units granted on 01/03/2025, and is to be executed on NASDAQ under Rule 144 procedures.

How many XERS shares did Steven Pieper sell in the past 3 months?

In the past 3 months, Steven Pieper sold 27,600 shares for $235,276.20 on 07/07/2026 and 17,400 shares for $147,900.00 on 07/06/2026, both reported as 10b5-1 plan sales of Xeris Biopharma common stock.

What is the approximate value of Steven Pieper’s planned XERS share sale?

The planned sale covers 20,000 Xeris Biopharma shares with an aggregate market value of $167,800.00, based on the Rule 144-related disclosure listing Morgan Stanley Smith Barney LLC as the broker.

Which broker is handling Steven Pieper’s planned XERS stock sale?

Morgan Stanley Smith Barney LLC Executive Financial Services, at 1 New York Plaza, is listed as the broker handling Steven Pieper’s planned sale of 20,000 Xeris Biopharma common shares under Rule 144 on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:38 PM Accepted by SEC EDGAR 08/12/2026 - 04:37 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001875714
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	XERIS BIOPHARMA HOLDINGS INC
SEC File Number	001-40880
Address of Issuer	1375 West Fulton Street, Suite 1300 Chicago ILLINOIS 60607
Phone	8444455704
Name of Person for Whose Account the Securities are To Be Sold	STEVEN PIEPER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	167800.00	182320306	08/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/03/2025	Restricted Stock Units	Issuer			20000	01/03/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for STEVEN PIEPER 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	07/07/2026	27600	235276.20
10b5-1 Sales for STEVEN PIEPER 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	07/06/2026	17400	147900.00

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units on 01/03/2025 and 01/31/2025.
Date of Notice	08/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Steven Pieper
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)